Leerink Partners analyst David Risinger has reiterated their bullish stance on CNTA stock, giving a Buy rating on June 4.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
David Risinger has given his Buy rating due to a combination of factors related to Centessa Pharmaceuticals’ ongoing developments and potential. The company’s orexin agonist program, particularly the ORX750, is expected to show a superior benefit-risk profile when Phase 2 results are released. Despite concerns about adverse events associated with orexin agonists, management has clarified that these comments were about competitors’ data, not Centessa’s ongoing trials.
The innovative design of the ORX750 Phase 2a trial, which involves unblinding after each dose level, sets it apart from competitor studies that focus on specific doses. This approach may provide more comprehensive insights into the drug’s efficacy and safety over time. Additionally, the anticipation of data disclosure across multiple indications by 2025 adds to the stock’s appeal, suggesting that the current market valuation may not fully reflect the company’s potential.
CNTA’s price has also changed moderately for the past six months – from $17.490 to $11.860, which is a -32.19% drop .